Credits Available: 5.0 AMA PRA Category 1 Credits

Description: The proposed activities will inform clinicians of recent evidence from clinical trials on the efficacy and safety of TROP2-directed antibody-drug conjugates (ADCs) in patients with progressive NSCLC, allowing them to quickly integrate new treatments into their practice when they become available. Clinicians will be updated on HER2 genomic alterations and apply appropriate testing methodologies per the National Comprehensive Cancer Network (NCCN) guidelines for NSCLC. Furthermore, participants will receive education on the successful management of NSCLC, including managing brain metastases, optimal HER2-targeted ADC dosing, and monitoring approaches for treatment-related adverse events (AEs). Finally, the proposed activities aim to educate participants on the importance of targeting HER3 and using HER3-directed ADCs in the management of NSCLC. The initiative will also provide information on the efficacy and safety of these ADCs based on clinical trial data, as well as strategies for recognizing and minimizing treatment-related AEs to enhance therapy adherence and improve patient outcomes.

CME/CE Accreditation Information

If you already have a Gather-ed account, please login

Email:
Password:

Register

Step 1 of 3

This program is intended for:
Target Professions: DO, MD, Nurse Practitioner, Physician Assistant
Target Specialties: Oncology

Brandon Chang

Kaiser Permanente
Pharmacist-in-Charge

Dr. Brandon Chang is a Board-certified Oncology Pharmacist and the Pharmacist-in-Charge at Kaiser Permanente Bellflower Oncology Pharmacy. He received his Doctor of Pharmacy degree from the University of Southern California (USC) and then completed a PGY1 and PGY2 Residency. He is passionate about precepting and serves as the primary preceptor in oncology at Kaiser Permanente Downey Medical Center for pharmacy residents and students. His main clinical interests include thoracic oncology, immunotherapy and supportive care.